Washington - Topical application of anti-tumor necrosis factor-? (TNF-?) monoclonal antibody (infliximab) produced dramatic improvement with wound closure in chronic, non-healing leg ulcers, said Markus Streit, M.D., department of dermatology, Inselspital, Bern, Switzerland.
